
    
      Alkotinib is an insulin receptor tyrosine kinase inhibitor that selectively inhibits
      anaplastic lymphoma Kinase and proto-oncogene protein ROS1。Alkotinib is expected to be used
      in the treatment of ALK positive and ROS1 positive metastatic non-small cell lung Cancer and
      other cancers include patients with non-small cell lung cancer who are resistant to treatment
      with the first generation ALK inhibitor, such as kezotinib。
    
  